Erschienen in:
24.02.2019 | Breast Oncology
Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come
verfasst von:
Elizabeth A. Mittendorf, MD, PhD, Tari A. King, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 5/2019
Einloggen, um Zugang zu erhalten
Excerpt
The recently revised 8th edition of the American Joint Committee on Cancer (AJCC) breast cancer staging system acknowledged the prognostic and predictive significance of underlying tumor biology by incorporating tumor grade, estrogen receptor (ER), progesterone receptor (PR), and HER2 receptor status into a pathologic prognostic stage.
1 In addition, based on the initial report of TAILORx (Trial Assigning Individualized Options for Treatment [Rx]), the committee revising the staging system took the bold step of incorporating genomic assays. Specifically, patients with ER+, HER2−, node-negative breast cancer with an Oncotype DX recurrence score (RS) < 11 enrolled on TAILORx had a 5-year distant recurrence-free survival of 99.3% with adjuvant endocrine therapy alone.
2 Based on this, the AJCC staging system added the modifier that any patient with T1-2N0, ER+, HER2- breast cancer and a RS < 11 would be assigned pathologic prognostic stage IA disease.
1 The committee acknowledged this is a rapidly evolving field and emerging data evaluating other assays and clinical scenarios would need to be evaluated to inform subsequent staging system revisions. …
